DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Inclusion Criteria

• •Adults ≥ 18 years of age who are willing and able to provide written informed consent
• •Have an ECOG performance status of ≤ 1. Subjects with an ECOG performance status of 2 may be enrolled with Medical Monitor approval.
• •Pathologically confirmed diagnosis of DLBCL, as defined by the 2016 World Health Organization classification including DLBCL NOS high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, Epstein-barr virus (EBV) positive DLBCL, and T cell rich B cell lymphoma (TCRBCL). Subjects with DLBCL transformed from indolent lymphoma (except for Richter's transformation) are eligible.
• •Subjects must have progressive disease following at least two (2) lines of prior systemic therapy for DLBCL; prior treatment must have included an anthracycline and rituximab (or another CD20-targeted agent).
• •Subjects must have failed or be ineligible for ASCT or CAR-T
• •Have at least one bi-dimensionally measurable lesion per Lugano (2014)
• •Willing to provide pre-treatment and on-treatment tumor biopsy tissue.
• •Meet protocol-specified laboratory requirements
• •Life expectancy \> 3 months.